Company Announcements

Notice of Results

Source: RNS
RNS Number : 9622O
Theracryf PLC
20 May 2024
 

A black background with blue letters Description automatically generated

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of FY results and Presentation via Investor Meet Company

 

Alderley Park, 20 May 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company's full year financial results for the year to 31 March 2024 will be released on Tuesday 28  May 2024.

 

The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.theracryf.com/investors.

 

Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via the Investor Meet Company platform at 3pm on Tuesday 28 May 2024.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 27 May 2024, 09:00 BST, or at any time during the live presentation. Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited.

 

Investors can sign up to Investor Meet Company HERE.

 

- Ends-

 

Enquiries

TheraCryf plc
Dr Huw Jones, CEO 
Toni Hänninen, CFO

Dr Helen Kuhlman, CBO

+44 (0)1625 315 090
enquiries@theracryf.com

Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks /
Harriet Ward (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Jack Kincade

+44 207 457 2020
theracryf@Instinctif.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORARMJTMTBBBPI